MRD-positive
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL (NCT03919526) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2019-08-11 |
Track MRD-positive automatically
Every clearance here is in the API, with alerts when new ones post.